New Delhi: Molbio Diagnosticsa medical tech the company has launched Truenat MTB-INH for testing the presence of isoniazid resistance in Mycobacterium tuberculosis infection (MDR-TB). The test is validated by ICMR and approved by CDSCO and can provide sample-to-test results in an hour’s time. It will enable early and accurate diagnosis of the deadly disease at the first point of patient contact, which is critical to achieving elimination goals.
MDR-TB is a serious public health issue. The growing occurrence of isoniazid mono-resistance is posing a major challenge to the treatment of Rifampicin Susceptible Isoniazid Mono-Resistant Tuberculosis (Hr-TB) patients who often end up with treatment failure, relapse and developing further drug resistance,
The new treatment recommendations issued by the WHO for treating Hr-TB patients necessitate the diagnosis of isonicotinic acid hydrazide (INH) resistance in Rifampicin susceptible patients. Thus, the detection of INH resistance is crucial for the treatment and control of MDR-TB.
As per the National Strategic Plan (NSP) 2017-2025 for TB eradication, the Government of India has taken a policy decision to decentralize and democratize access to advanced rapid molecular diagnostics for TB by introducing Truenat in every block of the country, to replace the currently used smear microscopy. Truenat MTB-INH will be immediately available to the existing 3300 Public Health Centers and Community Health Centers using Truenat under the National TB Elimination Program (NTEP). Truenat MTB-INH is also expected to play a major role internationally, in high TB-burden countries as well as countries that already have a policy in place for INH testing on all TB-positive samples.
Commenting on the launch, Sriram Natarajan, CEO, Founder, and Director, Molbio Diagnosticssaid, “Once introduced in all the blocks, every TB patient will have access to MDR TB testing at the same TB testing center with reporting on the same day, so correct treatment can also begin on the same day, thus enabling better treatment outcomes and bringing down the disease spread.
Highlighting the importance of real-time diagnostic tests, Dr Chandrasekhar Nair, CTO and Director, Molbio Diagnostics said, “Molecular methods such as Polymerase Chain Reaction (PCR) or Real-Time PCR are revolutionizing disease diagnosis and management. Truenat has been a game changer in this regard as a point-of-care molecular platform that offers over 40 tests right at the point of need.